Investigating the impact of CYP1B1 polymorphism on the response to tamoxifen in women with Breast cancer women

Abstract

Objectives
Primary Objective
Determine how CYP1B1 variants (rs1056836 and rs1056827) affect the response to tamoxifen in women with breast cancer.
Secondary objectives
1. To explore the linkage between CYP1B1 genotypes (rs1056836 -rs1056827) on clinical outcomes.
2. Test whether there is interaction between CYP1B1 genotypes (rs1056836 and rs1056827) and clinical factors.
Methods
The study involved 139 female breast cancer patients aged 45 and above at Imam Al-Hussein Medical City in Kerbala. Data was collected from clinical data, including weight, age, family history, and health problems. Blood samples were analyzed for biochemical parameters, including estradiol levels, tumor markers, and lipid profiles. The study aimed to investigate treatment responses and hormone levels in breast cancer patients, and also estimated high-density and low-density lipoprotein concentrations.
Results
The study revealed that there was a prevalence of excess weight, and most of them were overweight. The duration of Tamoxifen use was also a major attribute, with 86.3% taking it in 3-60 months. The majority of the patients had a family history of the disease, with the contribution of only 1.4% by smoking and hormone therapy. In breast cancer, the researchers also determined that there was a lack of findings that there was a strong genetic correlation between the genotype of the hormone receptor subtypes and the rs1056827 genotype.
Conclusion
genetic variation in CYP1B1 is shown to play a major role in tamoxifen response and treatment outcomes and affecting patient adherence to the drug